Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Immunology

Why Does MCAS Cause Sudden Anxiety and Panic Attacks?

At a Glance

Anxiety and panic attacks during an MCAS flare are physical reactions, not psychiatric ones. They occur when mast cells release a flood of inflammatory chemicals like histamine that cross the blood-brain barrier, directly triggering the brain's fear center and fight-or-flight response.

When a Mast Cell Activation Syndrome (MCAS) flare begins, experiencing a sudden, overwhelming sense of dread, panic, or anxiety is incredibly common—and it is a physical reaction, not a psychiatric one. During a flare, your mast cells inappropriately release a sudden cascade of inflammatory chemicals, such as histamine and cytokines, into your bloodstream [1][2]. These powerful mediators can disrupt and cross the blood-brain barrier, triggering direct inflammation in the central nervous system [3][4]. Your brain registers this chemical flood as an immediate threat, activating your body’s “fight-or-flight” alarm system and producing feelings of intense anxiety or impending doom before you even realize a physical flare has started [5][6].

How Mediators Cross the Blood-Brain Barrier

To understand why this happens, it helps to look at the biology of a mast cell flare. Mast cells are part of your immune system, packed with granules containing hundreds of chemical mediators. When triggered, they release these chemicals to protect your body.

In MCAS, mast cells are hyper-responsive and release these mediators inappropriately [1]. Some of these chemicals, particularly specific cytokines and histamine, have the ability to alter the permeability of the blood-brain barrier (BBB)—the protective shield that normally keeps toxins out of your brain [3][1]. Once the BBB is compromised, peripheral inflammatory signals enter the brain and activate microglia (your brain’s resident immune cells) [4][7]. This sudden neuroinflammation directly alters brain function, provoking neurological and psychiatric-seeming symptoms like sudden panic, brain fog, and intense anxiety [1][8].

The “Sense of Impending Doom” and Your Nervous System

Many patients describe a terrifying “sense of impending doom” right as a flare begins. This is driven by several overlapping biological pathways:

  • The HPA Axis and CRH Loop: Mast cell mediators interact directly with your brain’s stress center, the hypothalamic-pituitary-adrenal (HPA) axis [5]. This prompts the release of corticotropin-releasing hormone (CRH). CRH acts on the amygdala (the brain’s fear center) to generate anxiety-like behaviors, and it signals peripheral mast cells to release more chemicals, creating a vicious feed-forward loop [9][10].
  • Interoceptive Triggers: MCAS flares often cause rapid shifts in the autonomic nervous system, such as a sudden drop in blood pressure or a spiking heart rate [11][6]. Your vagus nerve detects these drastic physical shifts and sends urgent warning signals to your brain [12]. Your brain interprets these sudden cardiovascular changes as a life-threatening event, translating physical instability into a profound feeling of panic [11][13].

In short: The inflammatory chemicals hijack your brain’s fear center and scramble your nervous system’s warning signals, making your body panic even if you are perfectly safe.

MMCAS vs. MCAS: Is There a Difference?

When researching mast cell diseases, you may see a distinction between Monoclonal Mast Cell Activation Syndrome (MMCAS) and typical (idiopathic) MCAS.

  • MMCAS involves a genetically abnormal, “clonal” population of mast cells. It is usually diagnosed through a bone marrow biopsy looking for specific molecular markers, such as the KIT D816V mutation [14][15].
  • Typical MCAS (idiopathic MCAS) involves mast cells that appear genetically normal but still over-react. Because the cells are structurally normal, they often do not cause persistently elevated baseline labs (like serum tryptase), which makes capturing a flare so vital for diagnosis [14][16].

While the cellular defect differs, both conditions share the same core problem: excessive mediator release [2][17]. Current medical literature shows no definitive difference in the severity of neuropsychiatric symptoms, like panic or brain fog, between MMCAS and idiopathic MCAS [18][19].

What to Do When the “Doom” Hits

For many patients, these symptom patterns lead to a misdiagnosis of a primary anxiety or panic disorder before their MCAS is identified. Because the anxiety is driven by an allergic-type reaction, traditional grounding techniques or cognitive behavioral therapy (CBT) may not be enough on their own to stop the feeling.

Instead, treating the root cause—the chemical flood—is key. Research demonstrates that when patients with mast cell disorders are treated with targeted mast-cell-stabilizing therapies and antihistamines, their neuropsychiatric symptoms often significantly improve [2][1].

When you feel that sudden sense of dread:

  • Recognize it as a physical symptom: Remind yourself that this is a chemical surge, not a true psychiatric emergency. The feeling is temporary and will pass as the mediators clear your system.
  • Use your rescue plan: Taking your prescribed rescue medications—such as H1/H2 antihistamines (like cetirizine or famotidine) or mast cell stabilizers (like cromolyn sodium)—is the appropriate physiological response to this type of panic [2][1].
  • Support your nervous system: Once you have addressed the chemical aspect, you can use physical grounding techniques to help stabilize your heart rate and autonomic nervous system while the medication kicks in.

Common questions in this guide

Is the anxiety from MCAS a psychiatric problem?
No, the sudden anxiety and panic during an MCAS flare are physiological reactions. They happen when mast cells inappropriately release inflammatory chemicals that cross the blood-brain barrier and trigger your central nervous system's fight-or-flight response.
Why do I feel a sudden sense of impending doom before an MCAS flare?
This feeling occurs when mast cell mediators interact with your brain's stress center and cause rapid cardiovascular shifts, such as a spiking heart rate. Your brain interprets these sudden physical changes as a life-threatening event, resulting in a severe feeling of panic.
What should I do when MCAS causes a sudden panic attack?
Recognize that the feeling is a temporary chemical surge, not a true psychiatric emergency. Utilizing your prescribed rescue medications, such as antihistamines or mast cell stabilizers, targets the root cause by stopping the inflammatory chemical flood.
Is there a difference between MMCAS and typical MCAS in causing anxiety?
While Monoclonal Mast Cell Activation Syndrome (MMCAS) involves genetically abnormal mast cells and typical MCAS does not, both cause excessive chemical release. Current medical evidence shows no significant difference in the severity of panic or brain fog between the two.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How can we determine if my sudden anxiety is a primary psychiatric issue or a symptom of my mast cell flares?
  2. 2.Which H1 and H2 antihistamines or mast cell stabilizers would you recommend as part of a rescue plan for when these sudden neurological symptoms hit?
  3. 3.Since my baseline labs might be normal with idiopathic MCAS, what specific tests should we run during a flare to capture the mediator release causing my panic?
  4. 4.Do my symptoms warrant genetic testing or a bone marrow biopsy to rule out Monoclonal Mast Cell Activation Syndrome (MMCAS)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome.

    Weinstock LB, Afrin LB, Reiersen AM, et al.

    Brain, behavior, & immunity - health 2025; (48()):101048 doi:10.1016/j.bbih.2025.101048.

    PMID: 40686928
  2. 2

    Neuropsychiatric Manifestations of Mast Cell Activation Syndrome and Response to Mast-Cell-Directed Treatment: A Case Series.

    Weinstock LB, Nelson RM, Blitshteyn S

    Journal of personalized medicine 2023; (13(11)) doi:10.3390/jpm13111562.

    PMID: 38003876
  3. 3

    Mast Cells in Stress, Pain, Blood-Brain Barrier, Neuroinflammation and Alzheimer's Disease.

    Kempuraj D, Mentor S, Thangavel R, et al.

    Frontiers in cellular neuroscience 2019; (13()):54 doi:10.3389/fncel.2019.00054.

    PMID: 30837843
  4. 4

    Suppression of Brain Mast Cells Degranulation Inhibits Microglial Activation and Central Nervous System Inflammation.

    Dong H, Zhang X, Wang Y, et al.

    Molecular neurobiology 2017; (54(2)):997-1007 doi:10.1007/s12035-016-9720-x.

    PMID: 26797518
  5. 5

    Anxiety and nonpsychotic mental disorders in acute urticaria.

    Magen E, Merzon E, Ashkenazi S, et al.

    Brain, behavior, & immunity - health 2025; (48()):101088 doi:10.1016/j.bbih.2025.101088.

    PMID: 40896412
  6. 6

    The vagus nerve: a cornerstone for mental health and performance optimization in recreation and elite sports.

    Lopez Blanco C, Tyler WJ

    Frontiers in psychology 2025; (16()):1639866 doi:10.3389/fpsyg.2025.1639866.

    PMID: 40718569
  7. 7

    Mast Cell Activation, Neuroinflammation, and Tight Junction Protein Derangement in Acute Traumatic Brain Injury.

    Kempuraj D, Ahmed ME, Selvakumar GP, et al.

    Mediators of inflammation 2020; (2020()):4243953 doi:10.1155/2020/4243953.

    PMID: 32684835
  8. 8

    Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue.

    Theoharides TC, Cholevas C, Polyzoidis K, Politis A

    BioFactors (Oxford, England) 2021; (47(2)):232-241 doi:10.1002/biof.1726.

    PMID: 33847020
  9. 9

    Neuroimmune connections between corticotropin-releasing hormone and mast cells: novel strategies for the treatment of neurodegenerative diseases.

    Bhuiyan P, Wang YW, Sha HH, et al.

    Neural regeneration research 2021; (16(11)):2184-2197 doi:10.4103/1673-5374.310608.

    PMID: 33818491
  10. 10

    Topographic organization underlies intrinsic and morphological heterogeneity of central amygdala neurons expressing corticotropin-releasing hormone.

    Li JN, Chen K, Sheets PL

    The Journal of comparative neurology 2022; (530(13)):2286-2303 doi:10.1002/cne.25332.

    PMID: 35579999
  11. 11

    AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.

    Aziz Q, Harris LA, Goodman BP, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025; (23(8)):1291-1302 doi:10.1016/j.cgh.2025.02.015.

    PMID: 40387691
  12. 12

    Targeting the cholinergic anti-inflammatory pathway with vagus nerve stimulation in patients with Covid-19?

    Bonaz B, Sinniger V, Pellissier S

    Bioelectronic medicine 2020; (6()):15 doi:10.1186/s42234-020-00051-7.

    PMID: 32743022
  13. 13

    Restless legs syndrome is associated with mast cell activation syndrome.

    Weinstock LB, Walters AS, Brook JB, et al.

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2020; (16(3)):401-408 doi:10.5664/jcsm.8216.

    PMID: 31994488
  14. 14

    A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis.

    Carter MC, Desai A, Komarow HD, et al.

    The Journal of allergy and clinical immunology 2018; (141(1)):180-188.e3 doi:10.1016/j.jaci.2017.05.036.

    PMID: 28629749
  15. 15

    Characterization of patients with clonal mast cells in the bone marrow with clinical significance not otherwise specified.

    Ballul T, Sabato V, Valent P, et al.

    EClinicalMedicine 2025; (80()):103043 doi:10.1016/j.eclinm.2024.103043.

    PMID: 39877259
  16. 16

    Mast Cell Activation Syndrome and Gut Dysfunction: Diagnosis and Management.

    Hamilton MJ

    Current gastroenterology reports 2024; (26(4)):107-114 doi:10.1007/s11894-024-00924-w.

    PMID: 38353900
  17. 17

    COVID-19 and Multisystem Inflammatory Syndrome, or is it Mast Cell Activation Syndrome?

    Theoharides TC, Conti P

    Journal of biological regulators and homeostatic agents 2020; (34(5)):1633-1636 doi:10.23812/20-EDIT3.

    PMID: 33023287
  18. 18

    Mast cell activation syndrome: Current understanding and research needs.

    Castells M, Giannetti MP, Hamilton MJ, et al.

    The Journal of allergy and clinical immunology 2024; (154(2)):255-263 doi:10.1016/j.jaci.2024.05.025.

    PMID: 38851398
  19. 19

    Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab.

    Berry R, Hollingsworth P, Lucas M

    Clinical & translational immunology 2019; (8(10)):e01075 doi:10.1002/cti2.1075.

    PMID: 31576204

This page explains the biological link between MCAS and anxiety for educational purposes. Always consult your immunologist or healthcare provider before starting new antihistamines or mast cell stabilizers.

Get notified when new evidence is published on Mast Cell Activation Syndrome (MCAS).

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.